Zoledronic acid-d5

Zoledronic acid-d5 is deuterated labeled Zoledronic Acid. Zoledronic Acid (Zoledronate) is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic Acid inhibits the differentiation and apoptosis of osteoclasts. Zoledronic Acid also has anti-cancer effects[1].

Zoledronate-d5; CGP 42446-d5; CGP42446A-d5; ZOL 446-d5

12352005

Apoptosis; Autophagy; Bacterial; Isotope-Labeled Compounds

Isotope-Labeled Compounds

Anti-infection; Apoptosis; Autophagy; Others

Metabolism-protein/nucleotide metabolism

Cancer; Metabolic Disease

10 mM in DMSO

OC(P(O)(O)=O)(P(O)(O)=O)C([2H])([2H])N1C([2H])=C([2H])N=C1[2H]

C5H5D5N2O7P2

277.12

[1]Shea GKH, et al. Oral Zoledronic acid bisphosphonate for the treatment of chronic low back pain with associated Modic changes: A pilot randomized controlled trial. J Orthop Res. 2022 Feb 23.|[2]Lianwei Wang, et al. Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review. BMC Cancer. 2020; 20: 1059.|[3]Hyung Joon Kim, et al. Zoledronate Enhances Osteocyte-Mediated Osteoclast Differentiation by IL-6/RANKL Axis. Int J Mol Sci. 2019 Mar; 20 (6) : 1467.|[4]Xiao-Lin Huang, et al. Zoledronic acid inhibits osteoclast differentiation and function through the regulation of NF-κB and JNK signalling pathways. Int J Mol Med. 2019 Aug;44 (2) :582-592.|[5]XIN HUANG, et al. Dose-dependent inhibitory effects of zoledronic acid on osteoblast viability and function in vitro. Mol Med Rep. 2016 Jan; 13 (1) : 613-622.|[6]Samantha Pozzi, et al. High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. Clin Cancer Res. 2009 Sep 15;15 (18) :5829-39.|[7]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.

Room temperature

Isotope-Labeled Compounds